scholarly journals Association of physical inactivity with circulatory disease events and hospital treatment costs

2013 ◽  
pp. 111 ◽  
Author(s):  
Rachel Davey ◽  
Tom Cochrane
Keyword(s):  
Physical Inactivity ◽  
Treatment Costs ◽  
Hospital Treatment ◽  
Circulatory Disease

scholarly journals Hospital Treatment Costs and Factors Affecting These Costs in Community-Acquired Pneumonia

2015 ◽  
Vol 16 (3) ◽  
pp. 107-113 ◽  
Author(s):  
Fatma Tokgoz Akyil ◽  
Armagan Hazar ◽  
Ipek Erdem ◽  
Canan Pehlivan Ones ◽  
Murat Yalcinsoy ◽  
...  
Keyword(s):  
Community Acquired Pneumonia ◽  
Treatment Costs ◽  
Hospital Treatment ◽  
Factors Affecting

scholarly journals Hospital treatment costs and length of stay associated with hypertension and multimorbidity after hemorrhagic stroke

BMC Neurology ◽  
2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Adrian V. Specogna ◽  
Tanvir C. Turin ◽  
Scott B. Patten ◽  
Michael D. Hill
Keyword(s):  
Length Of Stay ◽  
Hemorrhagic Stroke ◽  
Treatment Costs ◽  
Hospital Treatment

scholarly journals TREATMENT COSTS FOR COVID-19 PATIENTS IN A TERTIARY HOSPITAL FROM SERBIA

2021 ◽  
Author(s):  
Predrag S. Sazdanovic ◽  
Slobodan Milisavljevic ◽  
Dragan R. Milovanovic ◽  
Slobodan M. Jankovic ◽  
Dejan Baskic ◽  
...  
Keyword(s):  
Fatal Outcome ◽  
Tertiary Hospital ◽  
Treatment Costs ◽  
Hospital Treatment ◽  
Insurance Fund ◽  
Southeast Europe ◽  
Middle Income ◽  
Tertiary Center ◽  
Illness Study ◽  
Comorbidity Index

ABSTRACTIntroductionAim of our study was to identify total costs of COVID-19 inpatients treatment in an upper-middle income country from Southeast Europe.MethodsThis retrospective, observational cost of illness study was performed from National Health Insurance Fund perspective and included a cohort of 118 males and 78 females admitted to COVID-19 ward units of a tertiary center, during the first wave of epidemics.ResultsThe median of total costs in the non-survivors’ subgroup (n=43) was 3279.16 Euro (4023.34, 355.20, 9909.61) which is higher than in the survivors (n=153) subgroup 747.10 Euro (1088.21, 46.71, 3265.91). The odds ratio of Charlson Comorbidity Index total score and every 100-Euros increase of patient’s total hospital treatment costs for fatal outcome were 1.804 (95% confidence interval 1.408-2.311, p<0.001) and 1.050 (1.029-1.072, p<0.001), respectively.ConclusionsDirect medical treatment costs for COVID-19 inpatients represent significant economic burden. The link between increased costs and unfavorable final outcome should be further explored.

scholarly journals Economic aspects of hospital treated pneumococcal pneumonia and the results of Pneumo 23 vaccine use in Serbia

2008 ◽  
Vol 136 (11-12) ◽  
pp. 625-628
Author(s):  
Tatjana Adzic ◽  
Ilija Rosic ◽  
Dragana Jovanovic ◽  
Snezana Medic-Stojanac
Keyword(s):  
Streptococcus Pneumoniae ◽  
Treatment Cost ◽  
Lung Diseases ◽  
Pneumococcal Pneumonia ◽  
Pneumococcal Infection ◽  
Treatment Costs ◽  
Hospital Treatment ◽  
Chronic Obstructive ◽  
Clinical Centre ◽  
One Year

INTRODUCTION In Serbia, there is a significant number of persons suffering of pneumococcal pneumonia. Persons aged 65 years or older, immunocompromised patients, patients with co-morbidities, such as chronic obstructive lung disease and congestive heart failure, are at the highest risk for developing pneumococcal pneumonia. Most of the patients are treated empirically, although it is often overlooked that Streptococcus pneumoniae can be resistant to the used antibiotics. The treatment costs of such inpatients and outpatients are very high. In Serbia, immunization of persons at risk to develop the diseases caused by Streptococcus pneumoniae is carried out using pneumococcus polysaccharide vaccine according to clinical indications. The exact number of immunized persons and the total number of registered patients are still unknown, but it is certain of being unjustifiably low. OBJECTIVE The goal of the study was to investigate, during a one-year period, the number and basic characteristics of persons hospitably treated for pneumonia, the type of cause of the infection, applied antibiotic medications, duration and costs of hospital treatment at the Institute for Lung Diseases and Tuberculosis of the Clinical Centre of Serbia in Belgrade. METHOD We retrospectively analyzed the medical records of patients with pneumonia treated at the Institute for Lung Diseases and Tuberculosis of the Clinical Centre of Serbia in Belgrade during 2006. RESULTS During the observed one-year period, 290 patients underwent hospital treatment, of whom the cause of the infection was confirmed in 116 (40%). The average duration of hospitalization was 12 days, with treatment cost of 32,031.74 RSD (402.42 EUR) per patient. The treatment cost per patient including general and intensive care was 18,290.01 RSD (229.78 EUR). The distribution cost of Pneumo 23 vaccine in Serbia, without purchase tax, was 746.90 RSD (9.38 EUR). CONCLUSION Pneumococcal pneumonia is a significant medical and economic problem for the healthcare system of Serbia. The use of antipneumococcal vaccination can be useful in decreasing the overall treatment costs related to pneumococcal infection.

Hospital treatment costs of exacerbations in COPD patients with indications for LTOT

2015 ◽  
Author(s):  
Nikolay Kyuchukov ◽  
Plamen Pavlov ◽  
Pavlina Glogovska ◽  
Tsania Popova ◽  
Nikolay Yanev ◽  
...  
Keyword(s):  
Treatment Costs ◽  
Hospital Treatment ◽  
Copd Patients

scholarly journals Smoking Attributable Hospital Treatment, Treatment Costs and Smoking Attributable Mortality in the Czech Republic in 2002

2007 ◽  
Vol 15 (2) ◽  
pp. 79-83 ◽  
Author(s):  
Hana Sovinová ◽  
Ladislav Csémy ◽  
Bohumír Procházka ◽  
Stanislava Kottnauerová
Keyword(s):  
Czech Republic ◽  
Treatment Costs ◽  
Attributable Mortality ◽  
Hospital Treatment ◽  
The Czech Republic

Treatment costs and quality of life of patients with peripheral arterial occlusive disease – the German perspective

VASA ◽  
2004 ◽  
Vol 33 (3) ◽  
pp. 145-153 ◽  
Author(s):  
Holler ◽  
Claes ◽  
von der Schulenburg
Keyword(s):  
Quality Of Life ◽  
Stage Iv ◽  
Indirect Costs ◽  
Treatment Costs ◽  
Hospital Treatment ◽  
Related Quality ◽  
Health Related ◽  
Physical Functions ◽  
Peripheral Arterial

Background: To objectify the debate about the restricted resources of the health system, examinations about the treatment costs and quality of life implications of different illnesses are necessary. The aims of the examination were the quantification of costs that are caused by a patient with PAD per year and the determination of the quality of life. Patients and methods: 280 patients (mean 66.6 years) in Fontaine stages II to IV were included in the study to determine their treatment costs for the year 2001 retrospectively from patient records. Health-related quality of life was recorded through the standardized questionnaires PAVK-86, SF-36 and EQ-5D. Results: A patient with PAD in stage IIa costs on average 1792.45 Euro, in stage IIb 2551.28 Euro, in stage III 4356.48 Euro and in stage IV 6225.89 Euro. The costs of the in-hospital treatment dominated the total result on average with 44.4% of the direct costs. Further cost factors were the drugs with 33.4%, the out-patient medical treatment with 9.9%, the expenditures for care with 6.7%, rehabilitation with 3.6% and adjuvants with a share of 1.9%. The indirect costs played a subordinate role with 9.67% of the total costs. The quality of life was clearly restricted in all stages of the PAD. The quality of life especially was strongly decreased from the Fontaine stage IIb on. The problems were mainly in the areas of the physical functions and pain. Conclusion: The study showed that the treatment of patients with PAD is very cost-intensive and that patients have to suffer from a considerable loss of quality of life.

Sign in / Sign up

Export Citation Format

Share Document